|
|
Home
Search
Study Topics
Glossary
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||||||||||||||
| Sponsored by: |
University Hospital, Strasbourg, France |
|---|---|
| Information provided by: | University Hospital, Strasbourg, France |
| ClinicalTrials.gov Identifier: | NCT00412048 |
Purpose
The aim of the protocol is to study the resting brain activation profile of 3 groups of people, using a new fMRI procedure, called fMRI-SAM. fMRI-SAM will be applied to 25 Alzheimer's disease (AD) patients, 25 patients suffering from amnestic - mild cognitive impairment (MCI) - a clinical picture which may be a prodromal form of AD - and 60 healthy controls. The first analysis of the data will search differences of brain activation profiles between the 3 groups. In the second step, the investigators will study the predictive value of fMRI-SAM to detect MCI patients who will later convert to AD.
| Condition | Intervention |
|---|---|
|
Alzheimer's Disease |
Procedure: fMRI to detect MCI patients who will convert to Alzheimer's disease |
| Study Type: | Observational |
| Study Design: | Prospective |
| Official Title: | Evaluation of fMRI-SAM in the Early Detection of Alzheimer's Disease. |
| Estimated Enrollment: | 110 |
| Study Start Date: | June 2007 |
| Estimated Study Completion Date: | December 2008 |
| Estimated Primary Completion Date: | December 2008 (Final data collection date for primary outcome measure) |
| Groups/Cohorts | Assigned Interventions |
|---|---|
| AD |
Procedure: fMRI to detect MCI patients who will convert to Alzheimer's disease
There is a fMRI to be realized in the 3 arms. No drug is administered
|
| MCI |
Procedure: fMRI to detect MCI patients who will convert to Alzheimer's disease
There is a fMRI to be realized in the 3 arms. No drug is administered
|
| Controls |
Procedure: fMRI to detect MCI patients who will convert to Alzheimer's disease
There is a fMRI to be realized in the 3 arms. No drug is administered
|
Eligibility| Ages Eligible for Study: | 55 Years to 75 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
| Sampling Method: | Non-Probability Sample |
Patients recruited during consultations
Inclusion criteria:
Exclusion criteria:
Contacts and Locations| Contact: François Sellal, MD | 33.3.88.11.66.62 | francois.sellal@chru-strasbourg.fr francois.sellal@ch-colmar.rss.fr |
| France | |
| Service de Neurologie, Hôpital Civil, | Recruiting |
| Strasbourg, France, 67091 | |
| Contact: Francois Sellal, MD 33.3.88.11.66.62 francois.sellal@chru-strasbourg.fr | |
| Principal Investigator: François Sellal, MD | |
| Sub-Investigator: Izzie Jacques Namer, MD | |
| Sub-Investigator: Stéphane Kremer, MD | |
| Sub-Investigator: Jack Foucher, MD | |
| Sub-Investigator: Frédéric Blanc, MD | |
| Principal Investigator: | Francois Sellal, MD | Hôpitaux Universitaires de Strasbourg |
More Information
| Responsible Party: | University Hospital, Strasbourg, France ( Emmanuel Lavoue, Directeur Adjoint de la DRCI ) |
| Study ID Numbers: | 3659 |
| Study First Received: | December 14, 2006 |
| Last Updated: | November 17, 2008 |
| ClinicalTrials.gov Identifier: | NCT00412048 |
| Health Authority: | France: Ministry of Health |
|
Delirium, Dementia, Amnestic, Cognitive Disorders Mental Disorders Alzheimer Disease Central Nervous System Diseases Neurodegenerative Diseases |
Brain Diseases Dementia Cognition Disorders Delirium |
|
Nervous System Diseases Tauopathies |
